Akura Medical Secures $53M in Series C Funding to Advance Thrombectomy Technology

Akura Medical, a California-based medical device company, has successfully closed a $53 million Series C financing round to accelerate the development of its innovative thrombectomy technologies. The funding, led by Qatar Investment Authority, will support the advancement of Akura's Katana thrombectomy system and NavIQ procedural planning software, both aimed at improving blood clot removal procedures.

Katana Thrombectomy System Enters Clinical Trials

The Katana thrombectomy system, designed to remove a range of clot types, recently received an investigational device exemption (IDE) from the U.S. Food and Drug Administration. This approval, granted in November 2024, paved the way for the QUADRA-PE trial, which began enrolling patients in February 2025. The study aims to evaluate the safety and effectiveness of the Katana system in patients with acute pulmonary embolism, a life-threatening condition caused by blood clots obstructing pulmonary arteries.

Akura's Katana device utilizes high-velocity saline jets to break up clots and prevent catheter clogging. The system's unique design allows it to tackle both soft and hard clots, addressing a significant challenge in current thrombectomy procedures. Additionally, the Katana system incorporates sensors that provide real-time pulmonary artery pressure data, enabling clinicians to monitor procedural progress effectively.

NavIQ Software Development and Future Plans

Part of the Series C funding will be allocated to the continued development of Akura's NavIQ software. This innovative tool is designed to convert CT angiograms into 3D models of pulmonary blood vessels, potentially enhancing procedural planning and precision in thrombectomy procedures.

The fresh capital will also support Akura's regulatory submissions and the completion of patient enrollment in the QUADRA-PE study. Furthermore, the company plans to establish a joint venture in Qatar, leveraging the support of the Qatar Investment Authority, which led the funding round.

Akura's Funding History and Market Position

This latest financing round builds upon Akura's previous fundraising successes. In 2023, the company secured $35 million in a round led by The Capital Partnership and Cormorant Asset Management, with participation from several other investors. Prior to that, Akura raised $25 million in 2022.

As Akura Medical continues to advance its thrombectomy portfolio, the company positions itself as a potential leader in the evolving landscape of blood clot removal technologies. With its focus on improving procedural precision and patient outcomes, Akura aims to address the limitations of existing thrombectomy devices in the market.